Advertisement

Topics

Companies Related to "A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals" [Most Relevant Company Matches] RSS

06:28 EST 17th February 2019 | BioPortfolio

Here are the most relevant search results for "A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals" found in our extensive corporate database of over 50,000 company records.

Showing "Phase Multicenter Clinical Trial Evaluate Safety Immunogenicity Immuno" Companies 1–25 of 6,600+

Extremely Relevant

Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical tri...


Quantum Clinical Research

Global Clinical Trial/Project Management Therapeutic Specialization Phase I Clinical Trial Mgmt Capabilities Phase II-III Capabilities Phase IIIb –IV Capabilities Post marketing Surveillance Treatment IND & Compassionate Use Regulatory Operations & QA Capabilities Worldwide Drug Safety Clinical Trial Monitoring CRA/Monitor Training Select Biometrics Capabilities

Protalex, Inc.

Protalex, Inc. is a clinical stage biopharmaceutical company that is developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including but not limited to, rheumatoid arthritis. Protalex’s lead product PRTX-100, which is formulated with a highly-purified form of staphylococcal protein A, has completed a Phase 1b...


SanBio Co., Ltd.

SanBio (TOKYO:4592) is a leading regenerative medical products company headquartered in Tokyo and Mountain View, California, with cell-based products in various stages of research, development and clinical trials. The company has completed enrollment for and is conducting a Phase 2b clinical trial for its proprietary regenerative medical product SB623 for ...

Relevant

Bionor Immuno AS

Bionor Immuno is a multidisciplinary drug discovery company located in Skien, Norway. The major focus of the company is to develop effective peptide based immunotherapies, against infectious diseases for which there is currently no effective vaccine or where existing treatments are poorly effective. Bionor Immuno AS aims to develop its therapeutic products through phase II clinical trials. Phase I...

Clinilabs, Inc

Clinilabs, Inc. is a privately-held, technology-based clinical trials organization that provides key drug development services to pharmaceutical and biotechnology companies involved in the development of new therapeutic drugs and medical devices. The company offers a wide range of services, including project development, project management, study execution at its dedicated site, electronic data ca...

AnorMED Inc.

AnorMED was founded in 1996 and listed on the TSX as “AOM” in 1999 and on the AMEX as "AOM" in 2005. To date, the Company has raised over $160 million to support its research and development programs. Over the past years AnorMED has grown to over 140 employees - the majority of which are scientists - including chemists, biochemists and biologists. Unlike many biotech companies that focus on d...

BioTechNews Denmark

TopoTarget and CuraGen Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for MesotheliomaTopoTarget A/S and CuraGen Corporation announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National ...

Polynoma, Inc.

Polynoma, Inc. is an oncology-focused biotechnology company based in San Diego, the United States of America. Polynoma’s lead product candidate is the therapeutic vaccine POL 103A for the treatment of melanoma. The Phase 3 trial of POL 103A was initiated based on two randomized, controlled Phase 2 trials that showed statistically significant efficacy ...

Favrille

We are a biopharmaceutical company focused on the development and commercialization of patient-specific immunotherapies for the treatment of cancer and other diseases of the immune system. We own a proprietary technology that enables us to efficiently develop and manufacture active immunotherapy products designed to stimulate a patient's own immune system to mount a specific and sustained response...

Aurinia Pharmaceuticals Inc.

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently enrolling patients in its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (“LN”). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal d...

resTORbio, Inc.

resTORbio, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio’s lead program is targeting the target of rapamycin complex 1 (TORC1) pathway to treat aging-related diseases and conditions with an initial focus on conditions caus...

Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of new drugs to treat patients with gastrointestinal (GI) diseases and disorders. Synergy’s lead drug, plecanatide, and next generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate ...

Arch Oncology, Inc.

Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer. The Company’s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative...

Vascular Dynamics, Inc.

Vascular Dynamics develops catheter-delivered technologies to bring a better quality of life to patients who are resistant to conventional treatments for hypertension. Vascular Dynamics was one of nine companies chosen in 2012 by the FDA to participate in the Early Feasibility Study IDE Pilot Program. The company is conducting open-label, controlled, multi...

ERT

Based in Philadelphia, PA, eResearchTechnology, Inc. (www.ert.com) is a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries. The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. It is also a leading provider of centrali...

Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Bost...

Phase Forward Incorporated

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Sc...

Genexine, Inc.

Genexine, Inc., listed on KOSDAQ (095700) since 2009, is a leading biotherapeutics company focused on immuno-oncology and orphan disease. Genexine has robust pipelines in clinical and pre-clinical stages based on long-acting Fc fusion technology and therapeutic DNA technology. In the clinical stage, Genexine has GX-H9 (long-acting human growth hormone, hGH...

Clinical Research Associate

Clinical Research Associate, also known as a Monitor, is an individual that oversees the progress and conduct of a clinical trial. A clinical trial is usually implemented by physicians at a hospital, clinic, or physician's office. The CRA is required to oversee the initiation, progress, and conduct of the clinical trial to ensure the scientific integrity of the data collected, and the protection o...

Tricida, Inc.

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Tricida has successfully...

GeoVax Labs, Inc.

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus - that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining re...

ADA Medical Ltd.

ADA Medical Ltd. is a Research Partnership Group of research professionals dedicated to the successful implementation and completion of clinical research projects for the pharmaceutical, biotechnology and medical device industries. We specialize in trial management and support for hospital based as well as outpatient Phase IIb through Phase IV clinical tri...

Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is focusing on development ...

Opsona Therapeutics Ltd

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004 ...


More From BioPortfolio on "A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks